RVMD's Pancreatic Cancer Breakthrough: Still a Buy After 150% Run?

Revolution Medicines (RVMD) received FDA approval in August for Rasonque (daraxonrasib) to treat previously treated metastatic pancreatic cancer. The drug nearly doubled overall survival in clinical trials, a result so impressive that it earned a standing ovation when presented at the American Society of Clinical Oncology in May.

Rasonque works by targeting RAS proteins, which are mutated in 20-30% of all cancers and were long considered undruggable. The drug attaches RAS to cyclophilin A, shutting off its ability to drive cell growth. This is Revolution's first approved product and validates its entire RAS-inhibitor platform.

The company reported $198 million in Rasonque sales in the first five weeks after launch, with a net loss of $407.5 million for the quarter. Despite the loss, the launch trajectory is strong, and the drug is expected to gain label expansions into other pancreatic cancer types and eventually non-small cell lung cancer (NSCLC).

Revolution's pipeline includes two other RAS inhibitors: zoldonrasib in three phase 3 trials for pancreatic ductal adenocarcinoma (PDAC) and NSCLC, and elironasib in phase 1/2 trials for NSCLC and solid tumors, with new trials in colon cancer. The stock is up over 150% year-to-date, yet analyst price targets average $258.84, well above current levels.

The approval of Rasonque is a major de-risking event for Revolution Medicines. It proves that the company's approach to targeting RAS proteins works, opening the door for a broad pipeline of drugs against multiple cancer types. RAS mutations are among the most common cancer drivers, and until now, they have been largely untreatable.

With Rasonque's success, Revolution is positioned to become a leader in RAS-targeted oncology. The drug's ability to nearly double survival in pancreatic cancer—a notoriously deadly disease—suggests blockbuster potential. The company estimates that 67,530 people are diagnosed with pancreatic cancer annually in the U.S. alone, and there are currently few effective treatments.

Beyond pancreatic cancer, Rasonque and the company's other RAS inhibitors are being tested in NSCLC and other solid tumors. Positive results in these larger markets could significantly expand the commercial opportunity. The pipeline includes three phase 3 trials for daraxonrasib, three for zoldonrasib, and early-stage trials for elironasib, providing multiple shots on goal.

Financially, Revolution is not yet profitable, but that's typical for a biotech transitioning to commercialization. The $198 million in first-five-week sales indicates strong demand. With over 90% institutional ownership and analyst targets significantly above the current price, the market is signaling confidence in the long-term potential. As the company executes on its launch and advances its pipeline, the stock could re-rate closer to established oncology leaders.